Molecular Testing

  •  

    The Power of Precision Medicine is Exemplified by Tempus

    With: Nike Beaubier, MDNamratha Sastry, PhD

    Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.

  •  

    Tumor Boards—What Are They and How Can They Help You?

    Julie Friedland, PhD

    One of the most powerful tools in cancer treatment today is the tumor board—a group of cancer experts who delve into individual cancer patients’ cases to help them explore their treatment options. As our world increasingly shifts online, virtual tumor boards enable many more patients to benefit from leading experts’ insights. Understanding how tumor boards work could help you get the most out of… Read more »

  •   George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes: 

    A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Academic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes: 

    Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.

    Go to full academic research paper from Clinical Epigenetics.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Pancreatic Cancer Survival Rates: What Do They Really Mean?

    Lola Rahib, PhD

    The American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic cancer is the same. Understanding what survival rates mean—and which factors can impact them—could help you navigate your or your loved one’s disease. What is the five-year relative survival rate for pancreatic cancer? In… Read more »

  •  

    The Challenges of Using Artificial Intelligence to Improve Cancer Treatment

    With: Jeff Shrager, PhDRazelle Kurzrock, MD

    In a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers a rebuttal. Shrager is Co-Founder and Director of Research at xCures, and was formerly Director of Research at Cancer Commons. He is also an… Read more »

  •   George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Molecularly matched treatment for pancreatic cancer may extend life for some patients.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology

    With: Razelle Kurzrock, MD

    A Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch, Inc. Email: razelle@curematch.com Q: The new understanding of many cancers brought about by molecular testing has led to a whole new field: precision oncology, which emphasizes targeted and immunotherapy. While promising, and sometimes spectacularly… Read more »

  •  

    Comprehensive Molecular Testing Needed for Stage IV Lung Cancer

    With: David Spigel, MD

    A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an expert medical oncologist with particular interest in lung cancer. The various forms of lung cancer are serious diagnoses, all potentially lethal malignancies. There are theoretical, investigational, and clinical justifications to perform molecular testing of… Read more »

  •   George Lundberg, MD

    Research paper from Nature curated by Editor in Chief George Lundberg, MD, who notes: 

    A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.

    Go to full paper published in Nature.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.